BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Monday

Key Points

• BioMarin will report Q1 2026 results after the market closes on Monday, May 4 (conference call 4:30 PM ET); analysts expect earnings of $0.7420 per share and revenue of $756.669 million.
• Shares traded at $53.18 (down ~0.2%) with a market capitalization of $10.28 billion, a P/E of 29.88, and a one‑year range of $50.76–$66.28.
• Analyst consensus is a "Moderate Buy" with an average target of $90.92 amid mixed firm-level ratings, while company insiders (two EVPs) recently sold shares and institutional investors own about 98.71% of the stock.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) is expected to announce its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect the company to announce earnings of $0.7420 per share and revenue of $756.6690 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

BioMarin Pharmaceutical Stock Down 0.2%

Shares of NASDAQ:BMRN traded down $0.12 during trading hours on Wednesday, reaching $53.18. The stock had a trading volume of 47,651 shares, compared to its average volume of 1,996,693. BioMarin Pharmaceutical has a 1 year low of $50.76 and a 1 year high of $66.28. The firm's 50 day moving average is $57.27 and its 200-day moving average is $56.29. The stock has a market capitalization of $10.28 billion, a price-to-earnings ratio of 29.88, a P/E/G ratio of 0.53 and a beta of 0.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.50 and a current ratio of 5.21.

Wall Street Analysts Forecast Growth

BMRN has been the topic of several recent analyst reports. HC Wainwright dropped their target price on BioMarin Pharmaceutical from $60.00 to $55.00 and set a "neutral" rating on the stock in a report on Wednesday, February 25th. Oppenheimer lowered their price objective on BioMarin Pharmaceutical from $98.00 to $95.00 and set an "outperform" rating for the company in a research report on Tuesday, February 24th. Weiss Ratings downgraded BioMarin Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, April 16th. Sanford C. Bernstein raised their target price on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 25th. Finally, Canaccord Genuity Group boosted their target price on BioMarin Pharmaceutical from $98.00 to $104.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $90.92.

Insider Activity

In other news, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the sale, the executive vice president owned 79,953 shares in the company, valued at approximately $4,833,958.38. The trade was a 17.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gregory R. Friberg sold 6,326 shares of the company's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares of the company's stock, valued at approximately $2,268,959.64. This trade represents a 14.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.85% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC increased its position in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock worth $39,000 after buying an additional 179 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in BioMarin Pharmaceutical during the third quarter worth approximately $40,000. Parallel Advisors LLC increased its position in BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock worth $42,000 after buying an additional 295 shares during the period. Meeder Asset Management Inc. increased its position in BioMarin Pharmaceutical by 1,974.1% during the fourth quarter. Meeder Asset Management Inc. now owns 1,763 shares of the biotechnology company's stock worth $105,000 after buying an additional 1,678 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new position in BioMarin Pharmaceutical during the fourth quarter worth approximately $201,000. Institutional investors and hedge funds own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.